|Fiscal Year||First Quarter||Second Quarter||Third Quarter||Information Circular||Annual Report|
Passive Foreign Investment Company
Disclaimer: this information is provided in order to assist shareholders in making calculations and does not constitute tax advice. Shareholders are advised to consult their own tax advisors concerning the overall tax consequences of the ownership of common shares arising in their own particular situations under united states federal, state, local or foreign law.
View our filings as a publicly listed company in Canada (TSX).
Our SEC filings as a publicly listed company in the United States (NASDAQ).
Oncolytics Biotech® Announces Poster Presentation at the 2018 Gastrointestinal Cancers Symposium Sponsored by ASCO in Patients with Relapsed Metastatic Adenocarcinoma of the Pancreas Read More
Oncolytics Biotech® Receives Favorable Final Advice Letter from the European Medicines Agency for REOLYSIN® in Metastatic Breast Cancer Read More